M. Sandström

发表

Esomeprazole FDA Approval in Children With GERD: Exposure-Matching and Exposure-Response

Justin C. Earp, C. Garnett, J. van der Walt, 2017, Journal of pediatric gastroenterology and nutrition.

Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients

J. Bergh, M. Karlsson, H. Lindman, 2006, Cancer Chemotherapy and Pharmacology.

The time course of body temperature, serum amyloid A protein, C-reactive protein and interleukin-6 in patients with bacterial infection during the initial 3 days of antibiotic therapy

A. Larsson, O. Cars, M. Karlsson, 2009, Scandinavian journal of infectious diseases.

A preliminary evaluation of a new enzyme immunoassay to detect Chlamydia pneumoniae-specific antibodies.

W. Boersma, M. Sandström, J. Boman, 2000, Journal of microbiological methods.

Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients.

J. Bergh, M. Karlsson, M. Fjällskog, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cytotoxic activity of a new paclitaxel formulation, Pacliex, in vitro and in vivo

M. Karlsson, R. Larsson, M. Sandström, 2004, Cancer Chemotherapy and Pharmacology.

Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicin-docetaxel regimen in breast cancer patients.

J. Bergh, M. Karlsson, H. Lindman, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The pharmacokinetics of epirubicin and docetaxel in combination in rats

M. Karlsson, M. Sandström, A. Freijs, 1999, Cancer Chemotherapy and Pharmacology.

Evaluation of drug interactions in the established FEC regimen in primary cultures of tumour cells from patients.

J. Bergh, R. Larsson, P. Nygren, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Developmental Pharmacokinetics of Gentamicin in Preterm and Term Neonates

E. Nielsen, L. Friberg, M. Sandström, 2009, Clinical pharmacokinetics.

Scaling the time-course of myelosuppression from rats to patients with a semi-physiological model

Mats O. Karlsson, Lena E. Friberg, Marie Sandström, 2010, Investigational New Drugs.

Semiphysiological model for the time course of leukocytes after varying schedules of 5-fluorouracil in rats.

M. Karlsson, L. Friberg, M. Sandström, 2000, The Journal of pharmacology and experimental therapeutics.

Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients

P. Ljungman, O. Ringdén, M. Sandström, 2001, Bone Marrow Transplantation.

A population pharmacokinetic model for cefuroxime using cystatin C as a marker of renal function.

A. Larsson, O. Cars, M. Karlsson, 2006, British journal of clinical pharmacology.

Determination of cefuroxime in human serum or plasma by liquid chromatography with electrospray tandem mass spectrometry.

M. Sandström, B. Jansson, Anders Viberg, 2004, Rapid communications in mass spectrometry : RCM.

Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders.

M. Karlsson, A. Fasth, M. Sandström, 1996, Bone marrow transplantation.

Phase I, multicenter, randomized, open-label study evaluating the pharmacokinetics and safety profile of repeated once-daily doses of intravenous esomeprazole in children 0 to 17 years of age.

P. Lundborg, G. Långström, G. Davidson, 2012, Clinical therapeutics.

Pharmacodynamics and systemic exposure of esomeprazole in preterm infants and term neonates with gastroesophageal reflux disease.

R. Haslam, P. Lundborg, T. Omari, 2009, The Journal of pediatrics.

Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients.

M O Karlsson, J. Bergh, M. Karlsson, 2003, European journal of cancer.

Pharmacokinetic/pharmacodynamic modelling in oncological drug development.

Mats O Karlsson, Lena E Friberg, Charlotte Kloft, 2005, Basic & clinical pharmacology & toxicology.

Semimechanistic Pharmacokinetic/Pharmacodynamic Model for Assessment of Activity of Antibacterial Agents from Time-Kill Curve Experiments

Mats O. Karlsson, O. Cars, M. Karlsson, 2006, Antimicrobial Agents and Chemotherapy.

Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression

Mats O. Karlsson, Johan E. Wallin, Lena E. Friberg, 2010, Cancer Chemotherapy and Pharmacology.

Failure to detect Chlamydia pneumoniae in the central nervous system of patients with MS

P. Sundström, M. Sandström, M. Hammerschlag, 2000, Neurology.

Haematological toxicity following different dosing schedules of 5-fluorouracil and epirubicin in rats.

M. Karlsson, M. Sandström, U. Wählby, 2000, Anticancer Research.